

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT7089300

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT

CONVEYING PARTY DATA

Name	Execution Date
VYNE THERAPEUTICS INC.	12/09/2021

RECEIVING PARTY DATA

Name:	VYNE PHARMACEUTICALS INC.
Street Address:	520 U.S. HIGHWAY 22
Internal Address:	SUITE 204
City:	BRIDGEWATER
State/Country:	NEW JERSEY
Postal Code:	08807

PROPERTY NUMBERS Total: 20

Property Type	Number
Patent Number:	8343945
Patent Number:	9161916
Patent Number:	8900553
Patent Number:	9549898
Application Number:	15999088
Application Number:	17322020
Patent Number:	8518376
Patent Number:	9795564
Patent Number:	9884017
Patent Number:	10213384
Patent Number:	10363216
Patent Number:	10588858
Application Number:	16779884
Patent Number:	10092588
Application Number:	16108799
Patent Number:	10029013
Patent Number:	10967063
Application Number:	17066752
Application Number:	16353911

PATENT

Property Type	Number
Application Number:	16624244
CORRESPONDENCE DATA	
Fax Number:	(202)408-4400
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	2024084000
Email:	jennifer.gomes@finnegan.com
Correspondent Name:	FINNEGAN, HENDERSON, FARABOW, GARRETT & DUNNER LLP
Address Line 1:	901 NEW YORK AVENUE, NW
Address Line 4:	WASHINGTON, D.C. 20001-4413
ATTORNEY DOCKET NUMBER:	13949.0999-00000
NAME OF SUBMITTER:	JENNIFER GOMES
SIGNATURE:	/Jennifer Gomes/
DATE SIGNED:	12/22/2021
Total Attachments: 4	
source=Patent Assignment Agreement 12_9_2021 US#page1.tif	
source=Patent Assignment Agreement 12_9_2021 US#page2.tif	
source=Patent Assignment Agreement 12_9_2021 US#page3.tif	
source=Patent Assignment Agreement 12_9_2021 US#page4.tif	

PATENT ASSIGNMENT AGREEMENT

WHEREAS, VYNE Therapeutics Inc. (hereinafter referred to as “Assignor”), a Delaware corporation, is the owner of the entire right, title, and interest in all countries throughout the world in and to the inventions disclosed and claimed in the issued patents listed on Schedule 1; and

WHEREAS, VYNE Pharmaceuticals Inc. (hereinafter referred to as “Assignee”), a Delaware corporation and a subsidiary of Assignor, is desirous of securing the entire right, title, and interest in all countries throughout the world in and to the inventions and issued patents listed on Schedule 1, and the Assignor is ready, willing and able to assign to the Assignee all such right, title and interest;

NOW THEREFORE, be it known that as of the Effective Date and in consideration of the foregoing and for other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, Assignor does hereby assign, transfer, and set over unto the Assignee, its lawful successors and assigns, as a contribution to capital of the Assignee intended to qualify for tax-free treatment under section 351 of the Internal Revenue Code of 1986, and the Assignee hereby accepts the entire right, title, and interest in and to all the inventions and issued patents listed on Schedule 1, and to all applications claiming priority to any issued patent or patent application listed on Schedule 1, and all extensions, renewals, and reissues thereof, and including the right to sue for past infringement; and Assignor hereby authorizes and requests the Commissioner of Patents and Trademarks of the United States and any official of any foreign country whose duty it is to issue patents on applications as described above, to issue all patents for these inventions to Assignee, its successors and assigns, in accordance with the terms of this Assignment;

AND, ASSIGNOR AND ASSIGNEE HEREBY further covenant and agree that duplicate assignments may be drawn up for each country or jurisdiction in accordance with local practice listing just the patents for that country or jurisdiction to facilitate recordation in each country or jurisdiction;

AND, ASSIGNEE HEREBY accepts this transfer and assignment. The legal transfer and assignment under this Assignment is effective as of December 9, 2021 (the “Effective Date”).

IN WITNESS WHEREOF, ASSIGNOR has executed this Assignment by its duly authorized representative.

Name: VVNE Therapeutics Inc.

Address: 520 U.S. Highway 22
Suite 204
Bridgewater, NJ 08807
U.S.A.

By: 

Name: David Domzalski

Title: Chief Executive Officer

Date: December 9, 2021

ACKNOWLEDGED BY:

Name: VVNE Pharmaceuticals Inc.

Address: 520 U.S. Highway 22
Suite 204
Bridgewater, NJ 08807
U.S.A.

By: 

Name: Tyler Zeronda

Title: Chief Financial Officer

Date: December 9, 2021

UNITED STATES

Serial No.	Publication No.	Patent No.	Title	Filing Date	Grant Date
US 12/795,164	US 2010/0310476	US 8343945	Carriers, Formulations, Methods For Formulating Unstable Active Agents For External Application And Uses Thereof	7 Jun 10	1 Jan 13
US 13/732,024	US 2013/0189191	US 9161916	Carriers, Formulations, Methods For Formulating Unstable Active Agents For External Application And Uses Thereof	31 Dec 12	20 Oct 15
US 12/795,213	US 2011/0212033	US 8900553	Oil And Liquid Silicone Foamable Carriers And Formulations	7 Jun 10	02 Dec 14
US 14/504,942	US 2015/0118164	US 9549898	Oil And Liquid Silicone Foamable Carriers And Formulations	2 Oct 14	24 Jan 17
US 15/999,088	US 2019/0091149		Oil foamable carriers and formulations	17 Aug 18	
US 17/322,020			Oil foamable carriers and formulations	17 May 21	
US 13/123,213	US 2011/0268665	US 8518376	Oil-Based Foamable Carriers And Formulations	6 Oct 09	27 Aug 13
US 13/967,546	US 2014/0050673	US 9795564	Oil-Based Foamable Carriers And Formulations	15 Aug 13	24 Oct 17
US 15/639,114	US 2017/0360705	US 9884017	Foamable Vehicles And Pharmaceutical Compositions Comprising Aprotic Polar Solvents And Uses Thereof	30 Jun 17	6 Feb 18
US 15/883,134	US 2018/0153804	US 10213384	Foamable Vehicles And Pharmaceutical Compositions Comprising Aprotic Polar Solvents And Uses Thereof	30 Jan 18	26 Feb 19
US 16/236,704	US 2019/0201339	US 10363216	Foamable Vehicles And Pharmaceutical Compositions Comprising Aprotic Polar Solvents And Uses Thereof	31 Dec 18	30 Jul 19
US 16/443,649	US 2019/0201339	US 10588858	Foamable Vehicles And Pharmaceutical Compositions Comprising Aprotic Polar Solvents And Uses Thereof	17 Jun 19	17 Mar 20
US 16/779,884	US 2020/0222320		Foamable Vehicles And Pharmaceutical Compositions Comprising Aprotic Polar Solvents And Uses Thereof	03 Feb 20	
US 15/401,743	US 2017/0216334	US 10092588	Foamable Compositions, Breakable Foams And Their Uses	9 Jan 17	9 Oct 18
US 16/108,799	US 2019/0054106		Foamable Compositions, Breakable Foams And Their Uses	22 Aug 18	

Serial No.	Publication No.	Patent No.	Title	Filing Date	Grant Date
US 13/499,709	US 2013/0011342	US 10029013	Surfactant-Free, Water-Free, Foamable Compositions And Breakable Foams And Their Uses	1 Oct 10	24 July 18
US 16/019,623	US 2019/0000980	US 10967063	Surfactant-Free, Water-Free, Foamable Compositions And Breakable Foams And Their Uses	27 June 18	06 Apr 21
US 17/066,752			Surfactant-Free, Water-Free, Foamable Compositions And Breakable Foams And Their Uses	9 Oct 20	
US 16/353,911	US 2019/0307778		Tetracycline Management of EGFR Inhibitor Associated Dermatoses	14 Mar 19	
US 16/624,244			Stable Topical Tetracycline Compositions	18 Dec 19	

PATENT

REEL: 058463 FRAME: 0172

RECORDED: 12/22/2021